速递｜首款减肥GLP-1仿制药获批！压力给到减重巨头

Core Insights - Teva Pharmaceuticals has achieved a significant milestone with the FDA's approval of the first GLP-1 generic drug, aimed at overweight adults and adolescents aged 12 to 17 who weigh over 60 kg (132 lbs) [2] - The GLP-1 therapy, initially used for type 2 diabetes treatment, mimics the natural GLP-1 hormone to regulate blood sugar levels [3] - The approval comes amid a global shortage of GLP-1 drugs, highlighting vulnerabilities in the international supply chain [6] Group 1: Market Dynamics - The GLP-1 market is projected to exceed $126 billion by 2029, with current sales for the original product reaching $165 million by June 2025 [7] - Teva's generic product, which is a version of liraglutide, is expected to be priced significantly lower than the original drugs, especially in markets outside the U.S. [5] - The demand for GLP-1 drugs has surged, outpacing supply due to challenges such as cold chain logistics and market volatility [6] Group 2: Competitive Landscape - Competing products like Wegovy and Ozempic are based on semaglutide and require weekly injections, while Teva's liraglutide requires daily administration due to its shorter half-life of approximately 13 hours [5] - There are ongoing lawsuits against GLP-1 drugs like Ozempic and Wegovy, alleging severe adverse effects, which may impact market perception and future sales [7] - The industry is witnessing an increasing demand for sustainable peptide synthesis, with various companies exploring new delivery methods and alternatives to GLP-1 therapies [9]